세계의 온바디 인젝터 시장

Global On-Body Injectors Market to Reach US$7.0 Billion by 2030

The global market for On-Body Injectors estimated at US$4.1 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. Electronic Injectors, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Mechanical Injectors segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.1% CAGR

The On-Body Injectors market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global On-Body Injectors Market - Key Trends & Drivers Summarized

Why Are On-Body Injectors Transforming Drug Delivery Practices?

On-body injectors (OBIs) are wearable drug delivery systems designed to administer large-volume biologics or medications subcutaneously over a controlled period. These devices are typically applied to the abdomen or arm and allow patients to self-administer treatments at home, reducing dependence on hospital-based infusions or frequent clinical visits. On-body injectors are particularly useful for chronic conditions that require regular dosing, such as cancer, autoimmune disorders, and diabetes.

Their adoption is rising due to growing demand for patient-centric, minimally invasive, and convenient drug delivery solutions. OBIs support better treatment adherence by allowing administration with minimal patient discomfort and without active engagement during delivery. They also enable delivery of high-viscosity biologics that cannot be injected rapidly with traditional prefilled syringes or autoinjectors. This shift toward wearable injectors aligns with broader trends in remote care and at-home therapeutics.

How Are Device Design and Technology Advancements Enhancing On-Body Injectors?

Technological innovation is shaping the next generation of on-body injectors through improved ergonomics, safety, and functionality. Modern OBIs feature prefilled drug reservoirs, automatic needle insertion and retraction mechanisms, and audible or visual indicators to guide patients through the process. Some devices offer digital connectivity, enabling transmission of usage data to healthcare providers for remote monitoring and treatment management.

Miniaturization of components, enhanced skin adhesives, and integration of pressure sensors and micro-pumps are making devices more discreet and comfortable to wear. Drug delivery can now be controlled over durations ranging from a few minutes to several hours, allowing administration of volumes up to 5 mL or more. Compatibility with high-viscosity formulations is also improving, enabling subcutaneous delivery of monoclonal antibodies, hormones, and long-acting therapeutics that were previously limited to intravenous routes.

What Therapeutic and Market Trends Are Expanding the Use of OBIs?

Growing prevalence of chronic diseases and biologic drug approvals is driving demand for patient-friendly delivery systems like OBIs. In oncology, on-body delivery of drugs such as pegfilgrastim is enabling outpatient care models and reducing infection risk from clinic visits. In autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, OBIs allow regular biologic therapy without injection fatigue or travel burden.

Pharmaceutical companies are increasingly co-developing drug-device combination products, incorporating OBIs in clinical trials and commercialization plans. Regulatory bodies are encouraging such integrated development, recognizing the role of devices in improving therapy compliance. Additionally, payers and healthcare systems are supporting at-home administration to reduce hospitalization and infusion center costs. These trends are expanding the role of OBIs from niche biologics to broader chronic disease management.

What Factors Are Driving Growth in the On-Body Injectors Market?

Growth in the on-body injectors market is driven by several factors. Rising burden of chronic and lifestyle diseases is increasing demand for long-term drug delivery solutions. Advances in biologic formulations, including high-concentration and high-viscosity drugs, are driving need for wearable delivery platforms. Patient preference for self-administration and at-home treatment is accelerating adoption of OBIs, particularly in oncology, immunology, and endocrinology. Technological improvements in device design, safety, and digital integration are supporting regulatory approvals and market penetration. Additionally, healthcare cost pressures and the shift toward value-based care are encouraging pharmaceutical and device companies to invest in OBIs that reduce treatment complexity, improve adherence, and enhance patient quality of life. These factors collectively support strong momentum in wearable injector development and global market expansion.

SCOPE OF STUDY:

The report analyzes the On-Body Injectors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Electronic Injectors, Mechanical Injectors); Disease (Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease, Other Diseases); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AptarGroup Inc.
• BD (Becton, Dickinson & Co.)
• Coherus BioSciences, Inc.
• Debiotech SA
• E3D Elcam Drug Delivery Devices
• Enable Injections
• Gerresheimer AG
• Insulet Corporation
• LTS Lohmann Therapie-Systeme AG
• Medtronic plc
• Nemera
• Roche (Accu-Chek)
• Sanofi
• ScPharmaceuticals (ScPharma)
• Sensile Medical AG
• SteadyMed Therapeutics
• Stevanato Group
• West Pharmaceutical Services, Inc.
• Ypsomed AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • On-Body Injectors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Diseases Propels Demand for Self-Administered, Long-Acting Drug Delivery Devices
  • Shift Toward Home-Based Care Expands Addressable Market for Wearable and On-Body Injection Systems
  • Growth in Biologics and Large-Molecule Therapies Strengthens Business Case for On-Body Delivery Platforms
  • Increased Focus on Patient Adherence and Convenience Drives Adoption of Hands-Free Injection Devices
  • Advancements in Microelectronics and Battery Technologies Enhance Reliability and Portability of On-Body Injectors
  • Regulatory Support for Connected Health Solutions Spurs Development of Smart On-Body Devices with Monitoring Capabilities
  • Expansion of Subcutaneous Drug Formulations Generates Opportunities for Alternative to In-Clinic Infusion Therapy
  • Integration of Wireless Connectivity and App-Based Interfaces Promotes Real-Time Dose Tracking and Alerts
  • Rising Healthcare Costs and Workforce Shortages Accelerate Use of Automated Injection Systems to Reduce Hospital Dependence
  • Increase in FDA Approvals and CE Marking of Wearable Injectors Boosts Commercial Availability and Market Access
  • Patient-Centric Design Trends Spur Innovation in Painless, Low-Profile On-Body Injection Devices
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World On-Body Injectors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Electronic Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Electronic Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Mechanical Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Mechanical Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Diabetes Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Diabetes Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Immuno-Oncological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Immuno-Oncological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• JAPAN
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• CHINA
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• EUROPE
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• FRANCE
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• GERMANY
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• UNITED KINGDOM
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• ASIA-PACIFIC
  • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030

IV. COMPETITION